Target intelligence / Profile preview

Avian influenza virus hemagglutinin protein (HA)

Target
HA
Molecular classification
Viral envelope glycoprotein, Class I fusion protein
01

Overview

The avian influenza virus hemagglutinin protein is a trimeric glycoprotein found on the surface of influenza viruses, acting as the primary protein responsible for viral entry into host cells[1][2][3][4][5]. Hemagglutinin mediates two essential steps: binding to sialic acid–containing receptors on host cells (receptor binding) and triggering the fusion of the viral envelope with the host cell membrane (membrane fusion) in response to the low pH of endosomes[1][3][4][5]. It is synthesized as an inactive precursor (HA0), which is later cleaved into HA1 and HA2 subunits required for fusion competence; avian influenza strains often have specific cleavage sites associated with increased pathogenicity in some hosts[3][5]. HA is the main target of neutralizing antibodies and is the protein most commonly used for influenza vaccine formulation and diagnostic assays due to its immunogenicity and subtype diversity (e.g., H5 in H5N1, H7 in H7N9)[1][4][5]. Its rapid antigenic evolution is a key challenge for durable immune protection and therapeutic targeting.

Other names
Influenza hemagglutininHemagglutinin (HA)Influenza A hemagglutininIVA HAFlu HA
02

Mechanism of action

Inhibition of receptor binding (blocking HA-sialic acid interaction); Inhibition of membrane fusion (blocking conformational rearrangements required for viral entry); Induction of neutralizing antibodies (vaccination-mediated, targets HA head and stalk domains)

03

Biological functions

Viral attachment to host cellReceptor bindingMediating membrane fusionEntry of virus into host cell
04

Disease associations

Infection
05

Safety considerations

Antigenic drift and shift—high mutation rate of HA can render vaccines or antibody therapies ineffective season-to-season[5]Immune escape due to hypervariability in HA head region[5]Limited cross-strain protection by current vaccines
06

Interacting drugs

No direct small-molecule drugs, but multiple monoclonal antibodies and vaccines target HA protein[3][4][5]. Oseltamivir (Tamiflu) and zanamivir target neuraminidase, not hemagglutinin, but combination antibody therapies and experimental broad-spectrum antivirals targeting HA are in active research. Examples include monoclonal antibodies such as C05[5], CR6261, FI6v3, and others (mainly for passive immunotherapy and research).
07

Biomarkers

Antibody titers against hemagglutinin (used in hemagglutination inhibition assays for influenza immunity/Vaccine efficacy)Subtype-specific HA detection (e.g., H5 or H7 for avian influenza diagnostic tests)

Beyond the preview

Go deeper on Avian influenza virus hemagglutinin protein (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avian influenza virus hemagglutinin protein (HA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call